Shareholders are set to pocket 58 per cent of a $65 million settlement in a class action against Treasury Wine Estates if the deal is approved by a court at a hearing this month.
A BBC Studios Australia executive who alleged she was the victim of adverse action and discrimination after she exercised her workplace rights has dropped her suit against her employer.
Parkview Constructions is seeking to bring negligence claims against Bates Smart and McKenzie Group in a lawsuit over alleged combustible cladding at Australia Towers in Sydney Olympic Park.
A developer seeking to redevelop the site of the Hyde Park Inn has lost its bid for an extra 15 months to pay up over $95 million to the NSW branch of the RSL to settle the purchase, but a judge has handed it a win in the process for determining the final price tag for the deal.
Coombes Property Group has been awarded $200 million in compensation for Sydney Metro’s compulsory acquisition of its CBD property, despite contending it was entitled to $430 million.
The owners corporation of a 98-unit Parklea development by defunct builder Dyldam Developments has failed in its attempt to claim insurance for building defects in a property completed 17 years ago, with a court finding that time was up.
A NSW council has partially succeeded in its challenge to the approval of a proposed residential development near the Peace Park in Ashbury in Sydney’s Inner West. In November 2024, Commissioner Elizabeth Espinosa of the NSW Land and Environment Court ruled in favour of developer Hamptons Property Services, and granted it development consent for a…
Herbert Smith Freehills has bolstered its Brisbane energy practice by luring a pair of partners from Allens and Johnson Winter Slattery.
Dovetail has hit back at a lawsuit alleging its boss sexually assaulted the tech start-up’s female legal counsel, claiming it was a “consensual loving relationship”.
Generic drug maker Sandoz wants to shield information turned up by preliminary discovery orders from the eyes of Amgen patent attorneys in a spat over cheap versions of Amgen’s bone disease drugs, and says if they view the material they should be barred from prosecuting future related patents.